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The human aldo–keto reductase AKR1B10, originally identiﬁed as an aldose reductase-
like protein and human small intestine aldose reductase, is a cytosolic NADPH-dependent
reductase that metabolizes a variety of endogenous compounds, such as aromatic and
aliphatic aldehydes and dicarbonyl compounds, and some drug ketones. The enzyme is
highly expressed in solid tumors of several tissues including lung and liver, and as such
has received considerable interest as a relevant biomarker for the development of those
tumors. In addition, AKR1B10 has been recently reported to be signiﬁcantly up-regulated
in some cancer cell lines (medulloblastoma D341 and colon cancer HT29) acquiring resis-
tance toward chemotherapeutic agents (cyclophosphamide and mitomycin c), suggesting
the validity of the enzyme as a chemoresistance marker. Although the detailed information
on the AKR1B10-mediated mechanisms leading to the drug resistance process is not well
understood so far, the enzyme has been proposed to be involved in functional regulations of
cell proliferation andmetabolism of drugs and endogenous lipids during the development of
chemoresistance. This article reviews the current literature focusing mainly on expression
proﬁle and roles of AKR1B10 in the drug resistance of cancer cells. Recent developments
of AKR1B10 inhibitors and their usefulness in restoring sensitivity to anticancer drugs are
also reviewed.
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INTRODUCTION
The aldo–keto reductase (AKR) superfamily is a rapidly growing
group of NAD(P)(H)-dependent oxidoreductases that metabo-
lize carbohydrates, steroids, prostaglandins, and other endoge-
nous aldehydes and ketones, as well as xenobiotic compounds
(http://www.med.upenn.edu/akr/). Members of this superfam-
ily are classiﬁed into 15 families, and each family is subdivided
into several subfamilies based on their amino acid sequence sim-
ilarities. For examples, human aldehyde reductase and aldose
reductase are named AKR1A1 and AKR1B1, respectively. Four
human hydroxysteroid dehydrogenases (HSDs), 20α-HSD, type 3
3α-HSD, type 2 3α-HSD/type 5 17β-HSD, and type 1 3α-HSD, are
named AKR1C1, AKR1C2, AKR1C3, and AKR1C4, respectively,
and are also collectively called AKR1C isoforms. The structural,
biochemical, and physiological features of 14 human AKRs have
been reviewed (Matsunaga et al., 2006; Jin and Penning, 2007;
Barski et al., 2008). Among them, AKR1B1 is the most exten-
sively studied, because it is the ﬁrst enzyme of the polyol pathway
metabolizing glucose into sorbitol and implicated in the chronic
complications of diabetes such as retinopathy, neuropathy, and
nephropathy (Yabe-Nishimura, 1998). In addition, human aldose
reductase-like protein AKR1B10 has been recently regarded not
only as a potential diagnostic and/or prognostic marker in carci-
nomas and serum (Fukumoto et al., 2005; Luo et al., 2011), but also
as a therapeutic target for the prevention and treatment of several
types of cancer (Liu et al., 2009a). Since AKR1B10 was originally
identiﬁed as an up-regulated protein in hepatocellular carcinomas
(Cao et al., 1998), its overexpression is observed in other types
of cancer, and its involvement in the development of resistance
toward anticancer agents has been suggested. The purpose of this
article is to review recent advances on roles of AKR1B10 in cancer
cells and their drug resistance. In addition, we provide an update
on the usefulness of AKR1B10 inhibitors in restoring sensitivity to
anticancer drugs.
PROPERTIES OF AKR1B10 AND ITS ROLE IN CANCER CELLS
AKR1B10 is a 36-kDa cytosolic reductase that is similar toAKR1B1
in both amino acid sequence identity (71%) and tertiary struc-
ture with the (α/β)8 barrel topology (Gallego et al., 2007). Like
AKR1B1, AKR1B10 reduces a variety of aromatic and aliphatic
aldehydes, dicarbonyl compounds, and some drug ketones using
NADPH as the coenzyme (Cao et al., 1998; Martin et al., 2006;
Spite et al., 2007; Baba et al., 2009; Endo et al., 2009; Zhong et al.,
2009), and the reaction catalyzed by the enzyme follows an ordered
bi bi mechanism with the binding of coenzyme to the free enzyme
(Endo et al., 2009). However, AKR1B10 differs from AKR1B1 not
only in its inability to reduce glucose and xylose (Cao et al., 1998;
Crosas et al., 2003) and prostaglandin H2 (Kabututu et al., 2009),
but also in its high catalytic efﬁciency for retinals (Crosas et al.,
2003; Gallego et al., 2006), isoprenyl aldehydes (farnesal and ger-
anylgeranial; Endo et al., 2009), and cytotoxic aldehydes (acrolein
and 4-hydroxy-2-nonenal; Shen et al., 2011).
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AKR1B10 reduces all-trans-retinal, 9-cis-retinal, and 13-cis-
retinal to their corresponding retinols with low Km (0.6–13μM)
and high kcat/Km values (5.8–45min−1 μM−1; Crosas et al., 2003;
Gallego et al., 2006). Retinoids play a pivotal role in proliferation,
differentiation, and morphogenesis of many cell types through
their binding of retinoic acids to retinoic acid receptors or retinoid
X receptors (Bushue and Wan, 2010; Tang and Gudas, 2011).
Retinoic acids are signaling molecules for inducing cell differen-
tiation (Tang and Gudas, 2011), and are formed by sequential
oxidation of retinols (Figure 1A). AKR1B10 regulates the retinoic
acid homeostasis by decreasing the cellular levels of retinoic acids
through efﬁciently reducing retinals into retinols, and is thus
thought to participate in tumor development (Crosas et al., 2003;
Gallego et al., 2006, 2007; Ruiz et al., 2009).
AKR1B10 also efﬁciently reduces farnesal and geranylgeranial
into their alcohols (farnesol and geranylgeraniol) with low Km
(2.3 and 0.9μM, respectively) and high kcat/Km values (13 and
FIGURE 1 | Metabolism of retinoids (A) and isoprenoids (B). (A)
all-trans-Retinol, 13-cis-retinol, and 9-cis-retinol are oxidized to the
corresponding retinoic acids through retinals by alcohol dehydrogenases
(ADH) and aldehyde dehydrogenases (ALDH). Retinoic acids regulate cell
function including differentiation through binding to retinoic acid receptor
(RAR) and retinoid X receptor (RXR). AKR1B10 effectively reduces retinals
into retinols, and is considered to promote cell proliferation by inhibiting the
retinoic acid formation. (B) Farnesyl pyrophosphate, an isoprenoid
intermediate of the mevalonate pathway, is converted by its
dephosphorylation into farnesol, which is further oxidized into farnesal and
farnesoic acid by ADH and ALDH. Geranylgeranyl pyrophosphate is similarly
metabolized. The two isoprenyl pyrophosphates are used in the prenylation
of small G-proteins such as Ras, leading to activation of MAP kinase
cascade and resultant increase in proliferation potential of cells. AKR1B10
efﬁciently reduces farnesal and geranylgeranial to farnesol and
geranylgeraniol, respectively, which are phosphorylated into the isoprenyl
pyrophosphates. Up-regulation of AKR1B10 in carcinomas and
chemoresistant cancer cells may increase the cellular levels of the two
isoprenyl alcohols by reducing back their aldehyde metabolites, and then
promote proliferation of the cell.
11min−1 μM−1, respectively; Endo et al., 2009). Similar to the
retinoid metabolism, the isoprenyl aldehydes are the intermedi-
ates in the metabolism of farnesol and geranylgeraniol into their
carboxylic acids (farnesoic acid and geranylgeranoic acid; Endo
et al., 2011), as illustrated in Figure 1B. Farnesol and geranylgeran-
iol are phosphorylated to their pyrophosphates, which are used
for prenylation of cellular proteins including small G-proteins
that are responsible for cell proliferation through activation of
mitogen-activated protein (MAP) kinase cascade (Park and Beese,
1997; Sinensky, 2000). The reduction of the isoprenyl aldehydes
by AKR1B10 increases the cellular levels of farnesol and geranyl-
geraniol, which promote protein prenylation. AKR1B10 may also
participate in the tumor development by regulating isoprenoid
metabolism.
In addition to its role in detoxiﬁcation of cytotoxic carbonyl
compounds (Shen et al., 2011), AKR1B10 promotes fatty acid and
lipid synthesis by blocking the ubiquitin-dependent degradation
of acetyl-CoA carboxylase α, a key enzyme in fatty acid synthesis,
suggesting that the enzyme also promotes cell growth and survival
through modulating lipid synthesis and membrane function (Ma
et al., 2008; Wang et al., 2009). Although the following four roles
of AKR1B10 in cancer cells have been proposed: (a) detoxiﬁca-
tion of cytotoxic carbonyl compounds, (b) promoting fatty acid
and lipid synthesis, (c) reducing farnesal and geranylgeranial into
their alcohols, and (d) reducing all-trans-retinal, 9-cis-retinal, and
13-cis-retinal to their corresponding retinols, further studies are
needed to elucidate which is the key role in cellular growth and/or
survival of each types of cancer described below.
CANCER-ASSOCIATED OVEREXPRESSION OF AKR1B10
In contrast to ubiquitous distribution of AKR1B1 (Grimshaw
and Mathur, 1989), AKR1B10 is highly expressed in human gas-
trointestinal tract and adrenal gland, but its expression levels in
other tissues are low (Cao et al., 1998; Hyndman and Flynn,
1998; Fukumoto et al., 2005). Of the two AKRs, AKR1B10 is
signiﬁcantly up-regulated in large and small airways of healthy
smokers, while it is less detected in those of healthy non-smokers
(Pierrou et al., 2007; Zhang et al., 2008;Wang et al., 2010). The up-
regulation of AKR1B10 is possibly due to components in tobacco
smoke (Nagaraj et al., 2006; Penning and Lerman, 2008). In addi-
tion, the overexpression of AKR1B10 is reported in the following
malignant tumors. In lung cancer, AKR1B10, but not AKR1B1,
is overexpressed, and the incidence of its overexpression differs
depending on cancer types. Fukumoto et al. (2005) ﬁrst reported
the overexpression of AKR1B10 in most cases of squamous cell
lung carcinomas and 29% of adenocarcinomas, both of which
are also associated with smoking. The ﬁnding is conﬁrmed by
subsequent studies, inwhichAKR1B10 overexpression ismore fre-
quently detected in smokers with squamous cell lung cancer than
in non-smokers with the cancer or smokers with adenocarcino-
mas (Woenckhaus et al., 2006; Kim et al., 2007; Li et al., 2008; Kang
et al., 2011). Hence,AKR1B10 is considered as a potential diagnos-
tic marker of smoking-associated squamous cell lung carcinoma.
AKR1B10 activates pro-carcinogenic polycyclic aromatic hydro-
carbons in tobacco smoke by exhibiting dihydrodiol dehydroge-
nase activity (Quinn et al., 2008), suggesting a possibility that this
enzyme is involved in carcinogenesis of the smoking-associated
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lung carcinoma. In malignant liver tumors, both levels of AKR1B1
and AKR1B10 are increased, but the overexpression frequency of
AKR1B10 is higher than that of AKR1B1 (Cao et al., 1998; Scuric
et al., 1998; Lee et al., 2001; Teramoto et al., 2008; Satow et al.,
2010). Recent clinicopathological studies show that the expres-
sion of AKR1B10 differs depending on stages of hepatocellular
carcinomas: The enzyme is signiﬁcantly overexpressed in lower
tumor stages with underlying cirrhosis or viral hepatitis, whereas
it is down-regulated in advanced tumor stages with low-grade
of differentiation (Heringlake et al., 2010; Schmitz et al., 2011).
Thus, AKR1B10 may be a valuable biomarker of differentiation
and proliferation of liver tumor, and play a role in early phases
of hepatocarcinogenesis. The up-regulation of AKR1B10 is also
reported in uterine carcinomas (Yoshitake et al., 2007), cholangio-
carcinomas (Heringlake et al., 2010), early stage gastric tumor (Lee
et al., 2010), and esophageal carcinogenesis (Breton et al., 2008).
The cancer-associated overexpression of AKR1B10 probably
results from an adaptive response to oncogenic processes, but little
is known about its gene regulation. Liu et al. (2009b) character-
ized the promoter region of the AKR1B10 gene, which includes
multiple putative oncogenic and tumor suppressor protein bind-
ing sites, including the transcriptional factors c-Ets-1 and C/EBP,
the repressor protein p53, and the AP-1 oncogene. Nishinaka et al.
(2011) identiﬁed several putative regulatory motifs, such as AP-
1, NF-κB, and antioxidant response element, in a −3282 bp of
the 5′-ﬂanking region and 5′-untranslation region of AKR1B10
gene, and also suggest a possibility that a complex polymorphic
microsatellite in this region is implicated in the enzyme induc-
tion in response to certain stimuli such as carcinogens. Further
investigations on the regulatory mechanisms of AKR1B10 gene
expression are needed to elucidate the signiﬁcance of its induction
in cancer cells.
ALTERATION IN EXPRESSION LEVELS OF AKRs IN
CHEMORESISTANT CELLS
Chemotherapy is commonly utilized as a therapeutic approach
for many cancers. However, one of major problems occurring
during the therapy is the intrinsic or drug resistance of the can-
cer cells, which leads to malignant transformation and metastasis
of tumors. Previous studies proposed several candidate mole-
cules that play key roles in the mechanisms of chemoresistance.
One of the most recognized candidates is an efﬂux transporter
P-glycoprotein. As P-glycoprotein is called multidrug resistance
protein, its aberrant expression decreases the metabolic clearance
of the drugs through shortening its residence time in the cells
(Higgins, 2007). The chemoresistance of the cancer cells is also
provoked by high expression of an inhibitor of apoptosis (IAP)
family members, such as c-IAP1 (Yang and Li, 2000; Notarbar-
tolo et al., 2004), which is considered to inhibit apoptotic cell
death elicited by some chemotherapeutics, such as cisplatin and
doxorubicin, through directly interacting with caspases and then
abolishing their pro-apoptotic actions (Vaziri et al., 2003; Tirrò
et al., 2006). Other resistance-related factors are growth factor
receptors and the ubiquitin–proteasome system. Binding of lig-
ands to ﬁbroblast growth factor receptor-1 and -3 activates both
signalings of MAP kinase and phosphoinositide 3-kinase (Roidl
et al., 2009; Tomlinson et al., 2012). Therefore, overexpression
of the growth factor receptors may enhance capacities of resis-
tant cells to proliferate, and protect from fatal damage induced
by anticancer drugs. The ubiquitin–proteasome system, a large
multi-subunit complex that cleaves damaged and misfolded pro-
teins, is thought to be activated with cancer chemoresistance.
The involvement of proteasomes in the chemoresistance is obvi-
ous from data that treatment with proteasome inhibitors MG132
and bortezomib induces multidrug resistance-associated protein
2 in human colon cancers (Loefﬂer-Ragg et al., 2009; Ebert et al.,
2011). In addition, the proteasome modulates the expression of
transcription factors, such as NF-κB, p53, c-Jun, and c-Fos, that
participate in the mechanisms of cell proliferation and differ-
entiation (Cory and Cory, 2002; Li et al., 2007). Moreover, the
ubiquitin–proteasome system appears to regulate cellular suscep-
tibility to death by controlling the balance between pro-apoptotic
caspases and anti-apoptotic Bcl and IAPs (Almond and Cohen,
2002).
A growing body of evidence implicates some members of the
AKR superfamily as new candidates that are involved in acquisition
of chemoresistance. Among the members, AKR1B1, AKR1B10,
and three AKR1C isoforms (AKR1C1, AKR1C2, and AKR1C3)
are reported to be up-regulated in several cancers exposed to
anticancer drugs (Table 1). Although clinical studies are few,
Chen et al. (2005) showed that the three AKR1C isoforms are
up-regulated in ovarian cancers, in which their overexpression
extents in cases resistant to cisplatin are much higher than those
in cisplatin-sensitive ones. Ueda et al. (2006) also reported that
AKR1C1/1C2 are highly expressed in uterine cervical cancer with
papillomavirus infection, and suggests that their high expres-
sion is closely associated with drug resistance to cisplatin and
anthracyclines.
Studies using the resistant phenotypes of cancer cells prepared
by exposure to anticancer drugs provided some informative results
concerning the relationship of the AKR expression with the drug
resistance. The overexpression of the three AKR1C isoforms due
to cisplatin resistance is observed in resistant phenotypes of ovar-
ian cancer cells (Deng et al., 2002; Chen et al., 2005, 2008). In
the resistance to anthracyclines, resistance of breast tumor cells
to doxorubicin and epirubicin increases the expression levels of
AKR1C2 and AKR1C3 (Veitch et al., 2009), and daunorubicin-
resistant variant cells of stomach cancer highly express the mRNAs
for AKR1B1 and AKR1C2 (Ax et al., 2000). In the resistance to
other agents, magnitude of resistance to cyclophosphamide (in
medulloblastoma) and methotrexate (in colon cancer cells) is cor-
related with up-regulation of AKR1B10 and AKR1C1, respectively
(Bacolod et al., 2008; Selga et al., 2008). We recently found high
expression of AKR1B10 in mitomycin c-resistant phenotypes of
colon cancer HT29 cells (Matsunaga et al., 2011). In addition to
the studies using the resistant phenotypes, cell-based experimental
techniques of transgenesis and small RNA interference elucidate
crucial roles of the ﬁve enzymes in chemoresistance of cells derived
from various cancers, as listed in Table 1.
Gain of resistance to platinum drugs, cisplatin, and carbo-
platin, increases the expression levels of AKR1C1 and AKR1C2
in cells derived from several cancers of ovary, cervix, lung, and
germ cell (Deng et al., 2004). However, the effect of resistance to
platinum drugs on the expression of AKRs in colon cancer has
www.frontiersin.org January 2012 | Volume 3 | Article 5 | 3
Matsunaga et al. AKR1B10 and drug-resistant cancers
Table 1 | Expression of AKRs in chemoresistant cancer cells.
Cancer Drug Up-regulated enzyme References
CLINICAL INVESTIGATIONS
Ovarian cancer Cisplatin AKR1C1, AKR1C2, AKR1C3 Chen et al. (2005)
Uterine cervical cancer Cisplatin AKR1C1, AKR1C2 Ueda et al. (2006)
Doxorubicin
INVESTIGATIONS USING RESISTANT PHENOTYPES
Ovarian cancer Cisplatin AKR1C1, AKR1C2, AKR1C3 Deng et al. (2002)
Chen et al. (2008)
Breast cancer Doxorubicin AKR1C2, AKR1C3 Veitch et al. (2009)
Epirubicin
Stomach cancer Daunorubicin AKR1B1, AKR1C2 Ax et al. (2000)
Medulloblastoma Cyclophosphamide AKR1B10 Bacolod et al. (2008)
Colon cancer Methotrexate AKR1C1 Selga et al. (2008)
Mitomycin c AKR1B10 Matsunaga et al. (2011)
INVESTIGATIONS BYTECHNIQUES OF GENE OVEREXPRESSIONAND SILENCING
Ovarian, cervical, and lung cancers Cisplatin AKR1C1, AKR1C2 Deng et al. (2004)
Carboplatin
Lung cancer Cisplatin AKR1C1, AKR1C2 Hung et al. (2006)
Adriamycin Wang et al. (2007)
Cutaneous cancer Bleomycin AKR1C1, AKR1C2 Chow et al. (2006)
Pancreas cancer Daunorubicin AKR1B1 Plebuch et al. (2007)
Breast cancer Doxorubicin AKR1C1 Loignon et al. (2009)
Paclitaxel
not been studied. To date, oxaliplatin (L-OHP), a third generation
platinum analog, is used for treatment of colon cancer, especially
the metastatic colorectal cancer. Our recent data on the effect of
L-OHP on the expression of AKRs in colon cancer HT29 cells
are shown below. We established low-grade (HT29/L-OHP2) and
high-grade (HT29/L-OHP20) resistant phenotypes, which show
resistance to the drug concentrations of 2 and 20μM, respec-
tively. The parental cells express AKR1C1,AKR1C2,AKR1C3, and
AKR1B10,but notAKR1B1,which is not detected even in the resis-
tant phenotypes. In the low-grade resistant cells, only AKR1B10 is
highly expressed in contrast to no apparent changes in the levels
of AKR1C1/1C2 and AKR1C3 (Figure 2). In contrast, the levels
of all AKRs are remarkably low in the high-grade resistant cells.
Since the HT29/L-OHP20 cells show 10-fold higher 26S protea-
some activity than the control cells, it is a persuasive argument
that the facilitation of the proteasome function is involved in the
down-regulation of the AKRs except for AKR1B1.
A well accepted mechanism for induction of AKR1B10,
AKR1C1, AKR1C2, and AKR1C3 is a nuclear factor erythroid
2-related factor 2 (Nrf2)-Kelch-like ECH-associated protein 1
(Keap1) system (Penning and Lerman, 2008; MacLeod et al., 2009;
Nishinaka et al., 2011; Agyeman et al., 2012). Under normal con-
ditions, the transcription factor Nrf2 tightly binds to Keap1 in the
cytosol and is degraded by the ubiquitin–proteasome system (Lau
et al., 2008). Nrf2 is dissociated from Keap1 in response to vari-
ous stimuli including reactive oxygen species (ROS; DeVries et al.,
2008) and electrophiles (Levonen et al., 2004), translocates into the
nuclei, and binds to antioxidant response element in genes to tran-
scriptionally induce proteins including the above AKRs. Recently,
FIGURE 2 | Expression levels of AKRs in parental and
L-OHP-resistant HT29 cells.The cells were grown in Dulbecco’s
modiﬁed Eagle’s medium supplemented with 10% fetal bovine serum
and antibiotics. The two L-OHP-resistant cells HT29/L-OHP2 and
HT29/L-OHP20 were prepared by exposing of the parental cells to
incremental stepwise concentrations (0.05–2 and 20μM, respectively)
of L-OHP. The amounts of AKR1B10, AKR1C1/1C2, and AKR1C3 in the
cell extracts were analyzed byWestern blotting using the antibodies
against the enzymes (Matsunaga et al., 2011). The density of the
immunoreactive band is normalized to that in the parental cells (taken as
100%), and expressed as the mean±SD of three independent
experiments. AKR1C1/1C2: total amount of AKR1C1 and AKR1C2
detected by the antibody cross-react with the two enzymes.
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Jiang et al. (2010) showed a relationship between abnormal acti-
vation of Nrf2 in type II endometrial cancer and the development
of chemoresistance. This is supported by ﬁndings that the overex-
pression and knockdown of Nrf2 result in increase and decrease,
respectively, in chemoresistance of some types of cancer cells (Cho
et al., 2008; Wang et al., 2008; Shim et al., 2009). Recent stud-
ies proposed two theories as the reasonable mechanistic base for
hyperactivation of Nrf2 in the cancer cells resistant to chemother-
apy. Loignon et al. (2009) showed that the Nrf2 hyperactivation is
due to down-regulation of Cullin 3 ubiquitin E3 ligase, an adap-
tor protein that speciﬁcally targets Nrf2 for degradation in the
ubiquitin–proteasome system, ﬁnally leading to sensitization to
doxorubicin and paclitaxel. In addition, mutations in Nrf2/Keap1
complex, especially in Keap1, to lose the Nrf2–Keap1 interaction
are identiﬁed in cancer cell lines showing chemoresistance (Singh
et al., 2006; Shibata et al., 2008). Thus, the Nrf2 activation is
considered as a crucial event in the development of chemoresis-
tance. In contrast, our data, together with studies listed in Table 1,
clearly indicate that expression patterns of the Nrf2-related genes
AKR1B10, AKR1C1/1C2, and AKR1C3 differ depending on both
cell types and anticancer drugs involved in resistance induction.
Hence, the different expression patterns of AKRs in chemoresis-
tant cancers may result from complex mechanisms that regulate
the synthesis and degradation of AKR proteins.
POSSIBLE ROLES OF AKR1B10 IN CHEMORESISTANT
CANCER CELLS
METABOLISM OF ANTICANCER DRUGS
AKR1B10 converts daunorubicin and idarubicin into less toxic
forms daunorubicinol and idarubicinol, respectively, by reducing
C13 ketone groups, with Km values ranging from 0.4 to 10mM
(Martin et al., 2006; Balendiran, 2009; Balendiran et al., 2009;
Bains et al., 2010; Zhong et al., 2011). The enzyme also reduces
doxorubicin and epirubicin albeit at lower rates (Bains et al., 2010;
Zhong et al., 2011). The artiﬁcial overexpression and inhibition
of AKR1B10 in 293 T cells result in decrease and increase, respec-
tively, in sensitivity to daunorubicin and idarubicin (Zhong et al.,
2011). These ﬁndings suggest that the AKR1B10 up-regulation
is responsible for the resistance to the anthracyclines. In addi-
tion, AKR1B10 is suggested to be involved in acquisition of the
resistance of medulloblastoma to cyclophosphamide through a
deactivation of a reactive cyclophosphamide metabolite aldophos-
phamide (Bacolod et al., 2008). Furthermore, we recently found
a signiﬁcant increase in NADPH-linked reductase activity toward
mitomycin c in the drug-resistant HT29 cells (unpublished data),
inwhichAKR1B10 is signiﬁcantly overexpressed (Matsunaga et al.,
2011). This may imply that the involvement of AKR1B10 in the
mitomycin c resistance is in part due to its ability to metabolize
this drug.
CELL PROLIFERATION
AKR1B10 is suggested to enhance cancer cell proliferation
(Zu et al., 2009), and its gene silencing suppresses growth of
human colon cancer HCT-8 cells (Yan et al., 2007). As shown
in Figure 3, overexpression of AKR1B10 in human leukemic
monocyte lymphoma U937 cells signiﬁcantly increases the cell
proliferation, which is abrogated by the addition of a potent
FIGURE 3 | Overexpression of AKR1B10 elevates proliferation potential
in U937 cells. U937 cells were cultured in Dulbecco’s modiﬁed Eagle’s
medium supplemented with 10% fetal bovine serum and antibiotics, and
transfected with the expression vector harboring the AKR1B10 cDNA as
described previously (Endo et al., 2009). The cell expressed AKR1B10,
which was not detected in the control cells transfected with the empty
vector. The cells were seeded at a density of 5×104 cells/well into a 24-well
multiplate, and cultured for 24, 48, or 72 h after addition of 0 (•), 5 (), or
20μM () of the AKR1B10 inhibitor, PHPC.The number of viable cells was
evaluated by the trypan blue-dye exclusion method, and is expressed as the
mean±SD of three independent experiments. Since no signiﬁcant effect of
PHPC on growth of the control cells was observed, only the proliferation of
the control cells without PHPC (◦) is depicted. *Signiﬁcant difference
(p<0.05) for the overexpressing cells without PHPC (•) from the control
cells (◦). #Signiﬁcant difference for the overexpressing cells with 20μM
PHPC () from those without the inhibitor (•).
AKR1B10 inhibitor (Z )-2-(4-methoxyphenylimino)-7-hydroxy-
N -(pyridine-2-yl)-2H -chromene-3-carboxamide (PHPC; Endo
et al., 2010a). These ﬁndings predict the involvement of AKR1B10
in proliferative potential of many cancer cells, which may be also
related to its overexpression in several cancer lesions (asmentioned
in Cancer-Associated Overexpression of AKR1B10).
The acquisition of multidrug resistance in a variety of cancer
cells has been shown to decrease tumorigenicity and prolong dou-
bling timedue to aG2/Mphase elongation (O’Loughlin et al., 2000;
De Angelis et al., 2006). However, to our knowledge, there have
been no reports on a relationship between AKR1B10 expression
and proliferative potential in chemoresistant cancer cells. When
the two L-OHP-resistant and the parental HT29 cells that are
described in Figure 2 are compared with respect to proliferation
rate and DNA replication potential, there is a strong correla-
tion between the two potentials and AKR1B10 level expressed
in the cells. As shown in Figure 4A, the parental cells exhibit
more rapid growth than HT29/L-OHP20 cells (with much lower
level of AKR1B10 than the parental cells). The involvement of
AKR1B10 in the proliferative potential is evidenced by signiﬁcant
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FIGURE 4 | Alteration in proliferation (A) and DNA replication potential
(B) of HT29 cells by gain of resistance to L-OHP. (A) HT29/L-OHP20
(closed symbols) and the parental cells (open symbols) were cultured in the
presence of 0 (circles), 5 (squares), or 20μM PHPC (triangles), and their
viable cell numbers were evaluated as described in Figure 2. Signiﬁcant
difference (p<0.05) for HT29/L-OHP20 cells with 0μM (•)* or the parental
cells with 20μM PHPC (Δ)# from the parental cells without PHPC (◦). (B)
Uptake of 5-bromo-2′-deoxyuridine (BrdU) into DNAs in the parental (HT29)
and resistant (HT29/L-OHP2 and HT29/L-OHP20) cells was measured using
a cell proliferation ELISA biotrak system (GE healthcare, Buckinghamshire,
UK). Value is normalized to that in the parental cells (taken as 100%), and
expressed as the mean±SD of three independent experiments.
suppression of the proliferation of the parental cells, but not
HT29/L-OHP20 cells, by the AKR1B10 inhibitor PHPC. In the
DNA replication potential (Figure 4B), the order of 5-bromo-2′-
deoxyuridine (BrdU) uptake is HT29/L-OHP2 cells> the parental
cells>HT29/L-OHP20 cells,which also correlateswith the expres-
sion levels of AKR1B10 shown inFigure 2. Flow cytometry analysis
of the resistant cells reveals that shortening of G1 phase and G2/M
phase elongation are associated with the magnitude of the L-
OHP resistance (Table 2), but not with the AKR1B10 expression.
Thus, AKR1B10 may participate in the proliferative mechanism
of L-OHP-resistant colon cancer cells, although it affects the cell
cycle less.
As mentioned in its roles in cancer cells,AKR1B10 is thought to
participate in tumor development by detoxifying cytotoxic alde-
hydes and modulating the retinoic acid homeostasis, isoprenoid
metabolism, and lipid metabolism. In contrast, little is known
Table 2 | Cell cycle of L-OHP-resistant HT29 cells.
Cells Phase (%)
G1 S G2/M
HT29 77.2 3.9 18.9
HT29/L-OHP2 58.3 14.2 27.5
HT29/L-OHP20 34.0 14.8 51.2
The parental HT29 cells and L-OHP-resistant cells (HT29/L-OHP2 and HT29/L-
OHP20) were ﬁxed with 70% ethanol, stained with propidium iodide, and
subjected to ﬂow cytometry.
about the roles of the up-regulated enzyme in chemoresistant can-
cer cells. We show evidence that the modulation of the isoprenoid
metabolism by AKR1B10 is involved in proliferative capacity of
the L-OHP-resistant HT29 cells (Figures 5 and 6). In the parental
HT29 cells (Figures 5A,B), the treatments with low concentra-
tions (1–2μM) of farnesol and farnesal facilitate the cell growth,
although their high doses (>5μM) lower the viable cell num-
bers as reported by Joo and Jetten (2010). The facilitation of cell
growth by the isoprenoids is further potentiated by the addition
of 4-hydroxyacetophenone, an inhibitor of aldehyde dehydroge-
nase 3A2 that catalyzes oxidation of farnesal into farnesoic acid
(Endo et al., 2011). In the analysis of DNA replication potential
(Figure 6), the BrdU uptake of the parental cells is elevated by
treating with farnesol or farnesal plus 4-hydroxyacetophenone.
The two treatments also enhance the DNA replication potential
of resistant HT29/L-OHP2 cells (which is originally high due to
the overexpression of AKR1B10), but has no stimulatory effect
on HT29/L-OHP20 cells with low AKR1B10 expression. In addi-
tion, activation of MEK1/2, also known as MAP kinase kinase,
is observed in HT29/L-OHP2 cells treated with 1μM farnesol or
farnesal (data not shown). These results may indicate that the
AKR1B10-mediated reduction of farnesal into farnesol not only
lessens colon cancer cell damage induced by farnesoic acid, but
also promotes the cell proliferation, probably due to protein far-
nesylation and activation of MAP kinase signaling as mentioned
above (Figure 1B). Thus, AKR1B10 overexpressed in the resistant
HT29/L-OHP2 cells participates in cell proliferation at least by
modulating the isoprenoid metabolism.
ANTIOXIDANT CAPACITY
Treatment of cancer cells with some chemotherapeutic agents
generates ROS, which modify biomolecules, nucleic acids, pro-
teins and lipids, and consequently forms highly reactive and toxic
carbonyl compounds, such as 4-hydroxy-2-nonenal and 4-oxo-2-
nonenal. In vitro enzyme assay showed that AKR1B10 effectively
reduces these lipid peroxidation-derived aldehydes into their cor-
responding alcohols (Liu et al., 2009a; Martin and Maser, 2009;
Wang et al., 2009; Shen et al., 2011), of which metabolism of HNE
by AKR1B10 is also veriﬁed in cell-based experiments (Zhong
et al., 2009; Shen et al., 2011). Knockdown of AKR1B10 gene by
small interference RNAs sensitizes colon cancer HCT-8 cells to
acrolein and crotonaldehyde (Yan et al., 2007).While many studies
support the detoxiﬁcation of lipid peroxidation-derived carbonyl
compounds as a role of AKR1B10 in tumor development, there
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FIGURE 5 | Facilitation of proliferation potential of HT29 cells by
treatment with farnesol (A) and farnesal (B). HT29 cells were pretreated
for 2 h without () or with 25μM 4-hydroxyacetophenone (), and then
treated for 48 h with the indicated concentrations of farnesol or farnesal.
The viable cell number was evaluated as noted in Figure 4. Value is
normalized to those in the control cells incubated without both isoprenoids
and 4-hydroxyacetophenone, and expressed as the mean±SD of three
independent experiments. *Signiﬁcant difference (p<0.05) from the
control cells.
is only one study concerning this role in chemoresistance. Mito-
mycin c produces ROS by its redox cycling, and the detoxiﬁcation
of lipid aldehydes byAKR1B10 is reported to be a major molecular
basis for gaining of the mitomycin c resistance of HT29 cells (Mat-
sunaga et al., 2011). It is possible that AKR1B10 exert this role in
cancer cells resistant to other anticancer drugs, such as bleomycin
FIGURE 6 | Isoprenoids promote DNA replication in L-OHP-resistant
HT29 cells.The parental HT29 cells and resistant HT29/L-OHP2 and
HT29/L-OHP20 cells were treated for 48 h without () or with 1μM farnesol
() or 1μM farnesal ( ), and the BrdU uptake was measured in the cells.
The cells were also pretreated for 2 h with 25μM 4-hydroxyacetophenone
prior to treating with 1μM farnesal ( ). Value is normalized to that in the
control HT29 cells incubated without both isoprenoids and
4-hydroxyacetophenone, and expressed as the mean±SD of three
independent experiments. *Signiﬁcant difference (p<0.05) from the
control cells.
(Khadir et al., 1999) and paclitaxel (Alexandre et al., 2007), that
are known to produce ROS.
REVERSAL OF CHEMORESISTANCE BY AKR1B10 INHIBITORS
AKR1B10 is considered as a key factor responsible for carcino-
genesis and chemoresistance as mentioned above. The enzyme
also exhibits different substrate proﬁles from AKR1B1, despite
their high structural homology. Therefore, development of potent
inhibitors speciﬁc to AKR1B10 is prerequisite for remedia-
tion of the enzyme-related diseases. Recently, cyclopentenone
prostaglandin A1 has been reported to be an AKR1B10 inhibitor,
which covalently binds to Cys299 near the active site of the
enzyme (Díez-Dacal et al., 2011). Interestingly, the inhibitor seems
to increase sensitivity of lung cancer A549 cells to doxorubicin.
Another study showed that polyphenol butein potently inhibits
dl-glyceraldehyde reductase activity of AKR1B10, with an IC50
value of 1.47μM (Song et al., 2010). We previously reported
steroid hormones, bile acids, and their metabolites as endogenous
AKR inhibitors (Endo et al., 2009).More recently, bymeans of nat-
ural products-based comprehensive analyses and in silico screening
approaches we have found curcumin derivatives (Matsunaga et al.,
2009), a ﬂuorone derivative (Zhao et al., 2010), chromene deriva-
tives (Endo et al., 2010a), non-steroidal antiinﬂammatory agents
(Endo et al., 2010b), and oleanolic acid (Takemura et al., 2011) to
be potent and/or speciﬁcAKR1B10 inhibitors. Structures and IC50
values of representativeAKR1B10 inhibitors are shown inFigure 7.
Among the inhibitors, a chromene derivative, PHPC, is the most
potent competitive inhibitor with an IC50 value of 6 nM, although
the AKR1B10 selectivity versus AKR1B1 is approximately twofold.
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FIGURE 7 | Structures and IC50 values of representative AKR1B10
inhibitors.The IC50 values for AKR1B10 (1B10) and AKR1B1 (1B1) are taken
from aEndo et al. (2010a), bEndo et al. (2009), cEndo et al. (2010b),
dMatsunaga et al. (2009), eTakemura et al. (2011).
In contrast, oleanolic acid inhibits AKR1B10 with the highest
selectivity ratio of 1370. The crystal structure of the enzyme-
NADP+–tolrestat ternary complex reveals that the inhibitor binds
to the active site of the enzyme (Gallego et al., 2006). Like tolrestat
(Endo et al., 2009), the above inhibitors are kinetically competi-
tive inhibitors, suggesting that they also bind to the same site as
that for tolrestat. Figure 8 shows the oleanolic acid-docked model,
on which tolrestat of the crystal structure was superimposed. The
two inhibitors occupied the substrate-binding site of the enzyme,
in which the 3β-hydroxy group of oleanolic acid and carboxyl
group of tolrestat are in close proximity to catalytically important
residues (Tyr49 and His111). There are differences in the orien-
tation of the other parts of the two molecules, and two residues
(Val301 and Gln303) are suggested to be key determinants of the
inhibitory selectivity of oleanolic acid for AKR1B10 over AKR1B1
(Takemura et al., 2011). The cell-based approaches show that the
two inhibitors (PHPC and oleanolic acid) remarkably reversed the
mitomycin c resistance of HT29 cells (Matsunaga et al., 2011;Take-
mura et al., 2011). Thus, potent and selective AKR1B10 inhibitor
would be useful for adjuvant medicine to subdue the development
of cancer resistance to chemotherapy.
CONCLUDING REMARKS
It is commonly assumed that chemoresistance of cancer cells is
induced with extraordinary enhancement of four capacities (1)
FIGURE 8 | Comparison of binding modes of oleanolic acid and
tolrestat in the AKR1B10–NADP+ complex.The oleanolic acid-docked
model (Takemura et al., 2011) is superimposed on the crystal structure of
tolrestat–NADP+–AKR1B10 ternary complex (Gallego et al., 2007), and only
tolrestat (pink) is shown with residues involving in the binding to oleanolic
acid (sky-blue).
to metabolize anticancer drugs into their harmless forms, (2) to
protect from damage evoked by them, (3) to secrete them into
extracellular space and (4) to grow in order to overcome their
lethal effects through activation of growth factor signaling path-
ways, of which, AKR1B10 is involved in the three capacities (1, 2,
and 4) as mentioned above. It is recently shown that the AKR1B10
activity is controlled by exchange of thiol–disulﬁde in Cys residues
that are attackedby reactive radicals (Shen et al., 2010). In addition,
analyses of the single-nucleotide polymorphism of AKR1B10 dis-
closed the presence of three kinds of mutations (P87S,M286T, and
N313D), which impair reductase activity of the enzyme toward
(1S)-1-indanol, albeit to a lesser degree (Bains et al., 2010). Thus,
it is speculated that the alteration in expression and/or activity
of AKR1B10 signiﬁcantly inﬂuences on the manifestation of drug
resistance and malignant progression. As mentioned above, there
is limited direct evidence in the literature regarding expression
proﬁles of the enzyme in cancers with chemoresistance. Addition-
ally, deﬁnite roles of other four AKRs in chemoresistant cells have
been not fully understood. Further studies are therefore needed
to monitor the expression of AKRs in various kinds of cancers
refractory to drugs.
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